Development of a novel peptide therapeutic for traumatic brain injury
Ended Project Grant Awarded Last action
- Award ID
- R44NS130776
- Recipient
-
Aivocode, Inc. UEI TLPZZJEMNND1
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $5,056,169
Award facts
- Assistance listing
- 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders
- Completion date
- Originally
- Place of performance
- California, USA
Award details come from USAspending.gov.
Description
- Abstract
- This direct-to-phase II application aims to complete the preclinical development activities required for the development of a novel treatment for moderate to severe traumatic brain injury (TBI), an area with a huge unmet need. TBI is characterized by an impact to the brain followed by a development of a secondary injury that results from processes initiated by the trauma. The secondary injury occurs in the hours and days following the primary injury and plays a large role in the brain damage and death that results from TBI. There are currently general management guidelines for patients with TBI with no specific neuroprotective interventions available. We propose to validate a novel therapeutic agent for treatment of moderate to severe TBI. Aivocode, INC. Has developed caqk, a proprietary peptide, for the management of TBI. Caqk specifically targets both penetrating and contusion type of brain injuries and has a pluripotent effect when administered early on in the injury by limiting the secondary damage in TBI. This effect results in improved healing of the injuries as well functional recovery in rodent model of TBI. In this application, we will conduct efficacy studies in PIG model of focal TBI and generate a pharmacokinetic profile in a gyrencephalic model of TBI. We will also complete pre-clinical studies that include CMC, formulation development and non-GLP toxicology studies needed for an IND (investigational new drug) application for the food and drug administration (FDA) to initiate clinical trials of caqk for treatment of TBI.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $87,001 | |
| Amendment | $1,193,627 | |
| Amendment | $1,193,627 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,290,957 | |
| Original award | $1,290,957 |
Quick answers
Who received award R44NS130776?
R44NS130776 was awarded to Aivocode, Inc. by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on April 1, 2023.
How much is award R44NS130776 worth?
$5,056,169 has been obligated on R44NS130776.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award